Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 46Squamous Cell Carcinoma of Head and Neck 23Lung Neoplasms 22Oropharyngeal Neoplasms 13Urinary Bladder Neoplasms 12Nasopharyngeal Carcinoma 12Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 8Biliary Tract Neoplasms 8Uterine Cervical Neoplasms 7Head and Neck Neoplasms 7Pancreatic Neoplasms 6Neoplasms 6Esophageal Squamous Cell Carcinoma 6Colorectal Neoplasms 6Cholangiocarcinoma 6Small Cell Lung Carcinoma 5Neoplasm Metastasis 5Mouth Neoplasms 5Endometrial Neoplasms 5Stomach Neoplasms 4Laryngeal Neoplasms 4Esophageal Neoplasms 4Carcinoma, Squamous Cell 4Ovarian Neoplasms 3Neoplasms by Site 3Mesothelioma, Malignant 3Lymphoid Interstitial Pneumonia 3Hypopharyngeal Neoplasms 3Carcinoma, Transitional Cell 3

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Cisplatin × 30 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡